Elixir completes seismic, remains on track for first spud

|

Published 16-SEP-2019 10:01 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Mongolian focused gas explorer, Elixir Energy Limited (ASX:EXR), this morning provided an update on current field operations in its 100% owned Nomgon IX coal bed methane (CBM) production sharing contract (PSC) in the south of Mongolia proximate to the Chinese border.

Elixir reports that the 2019 Nomgon IX Seismic Survey has now been completed with results due in six weeks. Preparation for the CSG drilling campaign on schedule and the spud for the first well is expected in late September/early October.

The seismic survey acquired 131 kilometres of 2D data over coal seam gas (CSG) leads at Ugtaal Uul, Nomgon North and Bag in the PSC (see map below).

The 30,000km2, 100% owned PSC was executed in September 2018 and has a 10+ year exploration period.

The company note that work was conducted safely, environmentally responsibly, efficiently and professionally by Mongolian owned Microseismic LLC with processing and interpretation to follow over the next six weeks.

Preparation for the CSG drilling campaign remains on schedule and Australian sourced permeability testing equipment has now arrived in Mongolia.

Desorption equipment sourced from the USA has been shipped and will arrive in Mongolia this week. In addition, Elixir is utilising CSG-experienced rig supervisors and other technical support from Australia and the USA and this team is ready to mobilise within the next few weeks.

For the drilling program, Elixir is using the highly respected Mongolian owned and operated drilling contractor Erdenedrilling LLC, who is currently awaiting the arrival of this US and Australian equipment.

Estimated spud for the first well (Ugtaal-1) remains the end of September/early October, while a second well location will be selected by around the end of this month.

Elixir’s Managing Director, Mr Neil Young, said “Our fully funded 2019 exploration program is going to plan. We have been very pleased with the professionalism and output of our Mongolian seismic contractors. We are now in the final pre-spud stages of our imminent drilling campaign, which has been designed to be the most technically advanced ever conducted for CSG in Mongolia.”

This video provides a look at Elixir’s Nomgon IX PSC and the Seismic Survey.

Good Oil Conference

Today’s news follows the company’s presentation at the Good Oil Conference in Perth last week. After attending the conference, a Patersons Securities resource analyst highlighted Elixir as “one to keep an eye on” in a brief note to clients. The analyst suggested that Elixir may be a good way to play the China gas thematic, something that has been missing since Sino Gas’s departure from the ASX.

The note explained that “The EXR team is technically astute, and includes Stephen Keleman (former manager of STO’s CSG business, Neil Young (ex-STO management, and has worked in Mongolia for the last eight years), and the ever humble Richard Cottee (Non-exec Chairman)”.

As I mentioned last week, in the article Oil and gas juniors looking the goods, Elixir is drawing comparisons to a number of other up and coming oil and gas explorers, including (what has almost certainly been Australia’s most successful oil and gas junior of the past two years), Galilee Energy (ASX:GLL), plus London’s Perto Matad (LSE:MATD), and Strike Energy (ASX:STX) and its JV partner Warrego Energy (ASX:WGO).



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X